Board of Directors

Nationality: British

Committee memberships: Nomination Committee (Chair), Remuneration Committee 

Date of appointment: Independent non-executive director since March 2020 and Non-executive Chair since July 2020

Responsibilities 

As Non-executive Chair of the Company, Dame Inga provides strong leadership to the Board, ensures the effective performance of the Board and leads by example by promoting a culture of openness and rigorous debate. She upholds the highest standards of corporate governance and works closely with the Group CEO to ensure implementation of Board-approved actions. She also facilitates constructive Board relations and the effective contribution of all non-executive directors and seeks to ensure that the Company maintains effective communications with shareholders and that the Board has a good understanding of their views. 

Contribution to the Company 

As an experienced leader, Dame Inga has close to 40 years of experience in global financial services, insurance and risk management in particular, and contributes a wealth of skills and experience to the Board. She brings valuable experience gained through her role as the CEO of Lloyd’s of London, where she initiated large-scale digital and cultural transformation programmes and led the business’ expansion into Dubai, China and India. She played a critical role in advancing diversity and inclusion initiatives across Lloyd’s and the international insurance sector. Her background provides a valuable balance to the Board and brings a different perspective to the Board’s debates.

Skills and experience

Dame Inga has extensive business management and leadership experience. From 2014 to 2018 she served as the first female CEO of Lloyd’s of London, the insurance and reinsurance market. Previously she held various senior leadership positions across the insurance sector, both in Switzerland and internationally, including at Converium, Zurich Insurance Group, Canopius and GE Insurance Solutions.

Key external appointments

Dame Inga currently serves as an independent member of the global strategy board of Clyde & Co LLP and as an independent nonexecutive director on the boards of Crawford & Company and London First. She also serves on the London Mayor’s Business Advisory Board, is Patron of Insuring Women’s Futures and Chair of the UK HIV Commission.

Qualifications

Dame Inga is a chartered insurer having qualified as an Associate of the Chartered Insurance Institute in 1987 and was appointed as Dame Commander of the Order of the British Empire in 2017 for services to the UK economy.

Nationality: South African

Committee membership: Clinical Performance and Sustainability Committee, Investment Committee

Date of appointment: Group CEO since June 2018

Responsibilities 

Dr Ronnie van der Merwe is responsible for driving and implementing operational decisions and strategy approved by the Board. He provides detailed insight into the operations of the business, enabling the Board to determine the feasibility and practicality of proposed strategies, goals and direction. 

Contribution to the Company 

As a qualified anaesthesiologist in private practice, Dr Van der Merwe gained extensive experience in trauma and elective anaesthesia, intensive care management, and the management of acute and chronic pain. During his involvement in the medical insurance industry, he gained healthcare data management and analytics expertise. He also displays proficiency in clinical leadership and management, as well as in developing and implementing strategic goals.

Dr Van der Merwe has extensive knowledge of Mediclinic’s international operations and a strong track record of managing quality and effectiveness. He established the Advanced Analytics, Clinical Information, Clinical Services and Health Information Management functions at Mediclinic, contributing to the growth of the Group.

Skills and experience

Dr Van der Merwe has Group-wide experience and possesses in-depth knowledge of Mediclinic’s workings, having held a variety of senior roles within the Company. He joined the Company in 1999 and as Chief Clinical Officer took responsibility for various aspects of the business prior to his appointment as executive director and Group CEO of Mediclinic. He was an executive director of Mediclinic International Ltd from 2010, up to the reverse takeover of Al Noor Hospitals Group plc. He was appointed as an executive director and Group CEO of Mediclinic, with effect from 1 June 2018 and also serves as a non-executive director on the board of Spire since 24 May 2018 under the terms of the shareholder agreement between Spire and Mediclinic.

Key external appointments

Non-executive director of Spire.

Qualifications

Van der Merwe holds an MBChB (Stellenbosch University); a DA (SA) (College of Anaesthetists of South Africa); the FCA (SA) (Fellowship of the College of Anaesthetists of South Africa); and has completed the Advanced Management Program (Harvard Business School).

Nationality: South African

Committee membership: Investment Committee    

Date of appointment: Group CFO since August 2016

Responsibilities 

As Group CFO, Mr Jurgens Myburgh has the primary responsibility for overseeing the financial planning and reporting, risk management and internal controls of the Group. In addition, he oversees the Group’s Corporate Finance, Investor Relations and Group Procurement functions.

Contribution to the Company 

Mr Myburgh is a qualified chartered accountant with broad financial and accounting experience obtained during his career of over 20 years. Since joining the Group, he has emphasised the importance of capital management and allocation informed by cost of capital across the Group and driven a structured approach to growth.

Skills and experience

Mr Myburgh has gained considerable financial and accounting experience since qualifying as a chartered accountant with KPMG in 2000. He joined The Standard Bank of South Africa Ltd in 2001 and was appointed as Head of Mergers and Acquisitions in 2009. Following this he served as CFO at Datatec Ltd, an international ICT Group, before joining Mediclinic as Group CFO in August 2016.

Key external appointments

Mr Myburgh has no external public appointments.

Qualifications

Mr Myburgh holds a BComm Hons in Accounting (University of Johannesburg) and is a qualified chartered accountant registered with the South African Institute of Chartered Accountants.

Nationality: British

Committee memberships: Audit and Risk Committee (Chair), Investment Committee, Nomination Committee  

Date of appointment: Independent non-executive director since February 2016, and Senior Independent Director and Chair of the Audit and Risk Committee since July 2019

Responsibilities 

As an independent non-executive director, Mr Alan Grieve is responsible for supporting the development of the Group’s strategy, providing strategic guidance and scrutinising management’s performance. He provides constructive challenge and advice, drawing on his skills, experience and judgement. As SID, Mr Grieve also acts as an intermediary for other directors and shareholders and as sounding board for the Chair. He leads the annual appraisal of the Chair’s performance and meets with the non-executive directors when necessary. He is available to shareholders should they have any concerns, should contact outside the standard communication channels be required.

Contribution to the Company 

Working as an executive and non-executivedirector across a wide range of business areas, Mr Grieve has gained comprehensive experience in finance and audit and risk management; he also has extensive knowledge of the healthcare sector. This equips him with a strong basis for assessing, and where appropriate, challenging, the financial and risk management framework, which makes him ideally suited to chair the Audit and Risk Committee.

Skills and experience

Mr Grieve has significant financial and accounting experience. He began his career in accountancy at the respective auditing firms now known as PwC and EY. He worked for Richemont, the Swiss luxury goods group, as Company Secretary from 1998 to 2004 and as Director of Corporate Affairs from 2004 to 2014. He served as an independent non-executive director of Mediclinic International Ltd from 2012 and as a director of Mediclinic Switzerland AG (now Hirslanden AG) between 2008 and 2012. He served as CFO of Reinet Investments Manager SA and Reinet Fund Manager SA from 2008 to 2011 and was the CEO from 2012 until he retired in 2014. He remains on the board of both companies as a non-executive director.

Key external appointments

Mr Grieve serves as a non-executive director on the boards of Reinet Investments Manager SA and Reinet Fund Manager SA.

Qualifications

Mr Grieve holds a BA Hons Business Administration (Heriot-Watt University) and is a member of the Institute of Chartered Accountants of Scotland.

Nationality: Emirati

Committee membership: Clinical Performance and Sustainability Committee

Date of appointment: Independent non-executive director since November 2017

Responsibilities 

As an independent non-executive director, Dr Muhadditha Al Hashimi is responsible for supporting the development of the Group’s strategy, providing strategic guidance and scrutinising management’s performance. She provides constructive challenge and advice, drawing on her skills, experience and judgement.

Contribution to the Company 

Dr Al Hashimi has extensive knowledge and experience of the healthcare sector and provides substantial strategic and tactical expertise in operations, fiscal management and negotiating strategic transactions. Dr Al Hashimi contributes valuable insights, especially into the Middle East operations of the Company, and has an excellent understanding of the broader geopolitical landscape, making her a valuable member of the Board.

Skills and experience

Dr Al Hashimi has more than 19 years’ experience in the healthcare and higher education industry in the UAE, together with strategic and tactical expertise in operations and fiscal management. Previous roles include that of Executive Dean of the Faculty of Health Sciences, Higher Colleges of Technology; acting Deputy Vice Chancellor of Academic Affairs at the Higher Colleges of Technology; CEO of the Mohammed Bin Rashid Al Maktoum Academic Medical Center in Dubai; Deputy CEO of Tatweer LLC; CEO of Dubai Healthcare City (both members of Dubai Holding); and a Director of Education of the Harvard Medical School Dubai Center. 

Key external appointments

Dr Al Hashimi is currently a member of the board of trustees and of the Audit and Compliance Committee of the University of Sharjah, and a member of the board of trustees of the UAE Nursing and Midwifery Council and the UAE Genetic Diseases Association. She is the Campus Director of Higher Colleges of Technology Sharjah Women’s College in the UAE.

Qualifications

Dr Al Hashimi holds a BS in Medical Technology (University of Minnesota); an MSc in Clinical Laboratory Services (University of Minnesota); and a Doctor of Public Health (University of Texas).

Nationality: South African

Committee memberships: Investment Committee, Nomination Committee

Date of appointment: Non-executive director since February 2016*

Responsibilities 

As the non-executive director representative of Remgro, Mr Jannie Durand is responsible for supporting the development of the Group’s strategy, providing strategic guidance and scrutinising management’s performance. He provides constructive challenge and advice, drawing on his skills, experience and judgement.

Contribution to the Company 

Mr Durand has extensive knowledge and more than 20 years of experience in the investment industry and brings substantial strategic and tactical expertise. He contributes valuable insights to the Board’s discussions, in particular by drawing on his skills and experience of the investment and capital markets, finance and accounting, risk management, development and implementation of strategy, as well as investor relations. 

Skills and experience

Mr Durand served as a non-executive director of Mediclinic International Ltd from 2012 up until the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Ltd in 2016. He joined the Rembrandt Group in 1996 and in 2012 was appointed as the CEO of Remgro, which holds a 44.56% interest in the Company. In his role as CEO of Remgro, Mr Durand brings more than 20 years’ experience in the investment industry.

Key external appointments

Mr Durand currently acts as a non-executive chair for the following listed companies within the Remgro group: Distell Group Holdings Ltd, RCL Foods Ltd, RMB Holdings Ltd and Rand Merchant Investment Holdings Ltd.

Qualifications

Mr Durand holds a BAcc Hons in Accountancy (Stellenbosch University); an MPhil in Management Studies (Oxford University); and is a qualified chartered accountant registered with the South African Institute of Chartered Accountants.

* Mr Uys, the Head of Strategic Investment at Remgro, was appointed as the alternate director to Mr Durand in April 2016. Prior to joining Remgro, Mr Uys was a founding member and ultimately became the CEO of the Vodacom Group. Mr Uys holds an MEng in Electronic Engineering (Stellenbosch University) and an Executive MBA (Stellenbosch University).

Nationality: British

Committee memberships: Clinical Performance and Sustainability Committee (Chair), Nomination Committee    

Date of appointment: Independent non-executive director since October 2017

Responsibilities 

As an independent non-executive director, Dr Felicity Harvey is responsible for supporting the development of the Group’s strategy, providing strategic guidance and scrutinising management’s performance. She provides constructive challenge and advice, drawing on her skills, experience and judgement.

Contribution to the Company 

Dr Harvey’s clinical (and public health) background provides valuable balance to the Board and brings a different perspective to the Board’s discussions and to the Clinical Performance and Sustainability Committee, which she chairs, particularly as developments in technology continue to accelerate. With increasing focus on matters such as sustainability, Dr Harvey, as the Chair ofthe Clinical Performance and Sustainability Committee, plays an important role in supporting management in developing and implementing the Company’s sustainability strategy.

Skills and experience

Throughout her career, Dr Harvey has gained an in-depth knowledge of the health sector, mainly through her work in the medical field. She was previously Director General for Public and International Health at the UK Department of Health; Director of the UK Prime Minister’s Delivery Unit; Head of the Medicines, Pharmacy and Industry Group at the Department of Health; Director of Prison Health at Her Majesty’s Prison Service; Head of Quality Management at NHS Executive; and Private Secretary to the Chief Medical Officer. Dr Harvey qualified in medicine in 1980 and was appointed CBE in 2008.

Key external appointments

Dr Harvey is a non-executive director of Guy’s and St Thomas’ NHS Foundation Trust, London; a visiting professor at the Institute of Global Health Innovation, Imperial College London; a trustee of Royal Trinity Hospice, London; and the Chair of the WHO Independent Oversight and Advisory Committee for Health Emergencies.

Qualifications

Dr Harvey holds an MBBS (St Bartholomew’s Medical College, University of London); a PgDip in Clinical Microbiology (The Royal London Hospital College, University of London); and an MBA (Henley Management College). She is an Honorary Fellow of the Royal College of Physicians and a Fellow of the Faculty of Public Health.

Nationality: South African

Committee membership: Investment Committee

Date of appointment: Non-executive director since August 2018 and the designated non-executive director for workforce engagement since April 2019

Responsibilities 

As a non-executive director, Mr Danie Meintjes is responsible for supporting the development of the Group’s strategy, providing strategic guidance and scrutinising management’s performance. He provides constructive challenge and advice, drawing on his skills, experience and judgement. In addition to his role as a non-executive director, as non-executive director responsible for workforce engagement, Mr Meintjes supports the Board in ensuring that workforce policiesand practices are consistent with the Company’s values and support Mediclinic’s long-term success. 

Contribution to the Company 

As the former Group CEO and prior to that, as divisional Human Resources Executive, Mr Meintjes led Mediclinic’s efforts to engage with, and invest in, the Company’s workforce. With his career background and in-depth knowledge of the Company, he is uniquely positioned to effectively oversee the Company’s engagement processes and evaluate the effectiveness and progress in this regard. He brings significant operational, strategic and risk management experience to the Board as well as extensive knowledge of the healthcare sector.

Skills and experience

Mr Meintjes served as the CEO of Mediclinic from 2010 up to his retirement on 1 June 2018, remaining on the Board as a non-executive director until 31 July 2018. He was appointed as an executive director and Group CEO of the Company on 15 February 2016. Prior to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Ltd in 2016, he served as the CEO of Mediclinic International Ltd from 2010. He served in various management positions in the Remgro group before joining Mediclinic in 1985 as the Hospital Manager of Mediclinic Sandton. He was appointed as a member of Mediclinic’s Executive Committee in 1995 and as a director in 1996. In 2006 he was seconded to serve as a senior executive of the Group’s operations in Dubai and appointed as the CEO of Mediclinic Middle East in 2007. He served as a non-executive director of Spire from 2015, a position from which he retired on 24 May 2018.

Key external appointments

Mr Meintjes serves as a non-executive director of Capitec Bank Holdings Ltd and Capitec Bank Ltd as well as Mercantile Bank Ltd.

Qualifications

Mr Meintjes holds a BPL Hons in Industrial Psychology (University of the Free State) and completed the Advanced Management Program (Harvard Business School).

Nationality: Swiss

Committee memberships: Nomination Committee, Remuneration Committee 

Date of appointment: Independent non-executive director since July 2018

Responsibilities

As an independent non-executive director, Dr Anja Oswald is responsible for supporting the development of the Group’s strategy, providing strategic guidance and scrutinising management’s performance. She provides constructive challenge and advice, drawing on her skills, experience and judgement. 

Contribution to the Company

Dr Oswald has extensive experience in the healthcare and medical operational sector. Her role as CEO of a well-established, private clinic provides her with a deep understanding and unique insights into day-to-day operations in the broader political and regulatory context of private healthcare in Switzerland. Dr Oswald brings a wealth of knowledge and practical experience to the Board, making her a valued member.

Skills and experience

Dr Oswald was previously Head of Medical and Pharmaceutical Services and Deputy Medical Officer in the Department of Health of the cantonal government in Basel and a member of various cantonal, regional and national committees. She was also CEO of a start-up company in the healthcare sector and worked several years as a medical doctor in various hospitals.

Key external appointments

Dr Oswald is the CEO of the Klinik Sonnenhalde and President of the Association of Private Hospitals in Basel. She also serves on the boards of Integrierte Psychiatrie Winterthur, the Alliance for a Free Healthcare System in Switzerland and Zippsafe AG.

Qualifications

Dr Oswald holds an MD-PhD specialising in Orthopaedic Surgery and Traumatology, as well as in Sports Medicine (University of Basel); an Executive MBA (University of Rochester-Bern); and a certificate of the Swiss Board School at the International Center for Corporate Governance of the University of St. Gallen.

Nationality: South African

Committee memberships: Audit and Risk Committee, Remuneration Committee (Chair)

Date of appointment: Independent non-executive director since February 2016

Responsibilities

As an independent non-executive director, Mr Trevor Petersen is responsible for supporting the development of the Group’s strategy, providing strategic guidance and scrutinising management’s performance. He provides constructive challenge and advice, drawing on his skills, experience and judgement.

Contribution to the Company

Mr Petersen brings significant experience, in-depth knowledge and corporate history of Mediclinic and the healthcare sector, having served as a director through the successful merger of Mediclinic International and Al Noor Hospitals Group plc in February 2016. Through his position as Chair of the South African Institute of Chartered Accountants in 2006 and 2007, Mr Petersen gained valuable experience in finance and accounting, which now informs his roles as the Chair of the Remuneration Committee and a member of the Audit and Risk Committee.

Skills and experience

Prior to the combination of the businesses of the Company (then Al Noor Hospitals Group plc) and Mediclinic International Ltd in 2016, Mr Petersen served as an independent non-executive director of Mediclinic International Ltd from 2012. In 1996, he resigned as a lecturer from the University of Cape Town to take up a partnership in the merged firm of PricewaterhouseCoopers Inc. He served as a partner of the national firm from 1997 to 2009 and as the partner-in-charge of Cape Town and Chair of the Western Cape region. He is an independent non-executive director on the board of Media24 (Pty) Ltd (a subsidiary of Naspers Ltd) and is currently the managing trustee of the Woodside Village Trust. He has served professional membership associations such as the South African Institute of Chartered Accountants and was elected the Chair of its national body in 2006 and 2007.

Key external appointments

Non-executive director of Media24 (Pty) Ltd.

Qualifications

Mr Petersen holds a BComm Hons in Accountancy (University of Cape Town) and is a qualified chartered accountant registered with the South African Institute of Chartered Accountants.

Nationality: British 

Committee memberships: Audit and Risk Committee, Remuneration Committee

Date of appointment: Independent non-executive director since 24 July 2019

Responsibilities

As an independent non-executive director, Mr Tom Singer is responsible for  supporting the development of the Group’s strategy, providing strategic guidance and scrutinising management’s performance. He provides constructive challenge and advice, drawing on his skills, experience and judgement.

Contribution to the Company

Mr Singer’s skills and experience, gained through his long and successful career in finance across a broad range of UK and international branded consumer businesses, including in the healthcare sector, provides important input. He also brings a thorough understanding of the UK-listed company environment. His career and background make him ideally suited to serve as a member of the Audit and Risk Committee.

Skills and experience

Previously Mr Singer served as CFO of InterContinental Hotels Group PLC, a leading international hotel group, and British United Provident Association (‘BUPA’), a provider of health insurance, care homes for the elderly and other health-related services including private hospitals. Earlier in his career, Mr Singer was CFO and Chief Operating Officer of William Hill PLC and Finance Director of Moss Bros PLC, having started his career in professional services and spending a total of 12 years at Price Waterhouse and McKinsey.

Key external appointments

Mr Singer currently serves as non-executive director on the board of DP Eurasia NV, an operator of pizza restaurants in Turkey and Russia.

Qualifications

Mr Singer holds a BSc Hons Finance and Accounting (University of Bristol); is a qualified chartered accountant; and attended the Advanced Management Programme (INSEAD).

Nationality: American

Committee memberships: Audit and Risk Committee, Clinical Performance and Sustainability Committee

Date of appointment: Independent non-executive director since 22 July 2020

Responsibilities

As an independent non-executive director, Mr Steve Weiner is responsible for  supporting the development of the Group’s strategy, providing strategic guidance and scrutinising management’s performance. He provides constructive challenge and advice, drawing on his skills, experience and judgement.

Contribution to the Company

Mr Weiner brings significant healthcare and international consumer goods experience in executive and non-executive finance and business transformation leadership roles in large, complex organisations in developed and developing markets.

Skills and experience

Mr Weiner spent most of his career in finance with the international consumer goods group Unilever, most recently as Group Controller responsible for performance management, accounting, reporting and control. He was also a member of Unilever's Global Finance Leadership Team, working closely with the group's board and Audit Committee.

Key external appointments

Mr Weiner is currently a non-executive director of Guys' and St Thomas' NHS Foundation Trust, one of the largest NHS Foundation Trusts in the UK, where he chairs the Transformation and Major Programmes Committee; is a member of the Strategy and Partnerships committee; and a member of the Audit Committee, which he chaired from 2014 to 2018. He is also a non-executive director and a member of the Finance and Commercial Committee of King's College Hospital NHS Foundation Trust, one of London's largest and busiest teaching hospitals. 

Qualifications

Mr Weiner holds a Masters in Finance from Columbia University and a Bachelor of Science in Management from Rutgers University.